https://www.selleckchem.com/pr....oducts/ziftomenib.ht
National regulatory regimes for supervising ongoing clinical trials are affected by external challenges, both international, such as harmonization of EU legislation, and national, such as critical reviews of incidents. This study examines how supervisory bodies dealing with ongoing trials respond to external challenges of the past two decades and engage in institutional work to maintain, repair, or improve the Dutch regulatory regime. International and national regulatory documents were analyzed and interviews (n = 27) were conducted
Like
Comment
Share
